Equities

Dizal Jiangsu Pharmaceutical Co Ltd

688192:SHH

Dizal Jiangsu Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)36.12
  • Today's Change-9.22 / -20.34%
  • Shares traded2.09m
  • 1 Year change-17.93%
  • Beta--
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Dizal Jiangsu Pharmaceutical Co Ltd is a China-based company mainly engaged in the exploration, research, development and commercialization of innovative biomedicine. The Company focuses on diseases such as malignant tumors and immune diseases. The main candidate innovative drugs in the Company's research and development (R&D) pipeline are DZD4205, DZD9008, DZD1516, DZD2269, DZD8586, DZD0095. The Company is still in the R&D stage.

  • Revenue in CNY (TTM)389.64m
  • Net income in CNY-837.22m
  • Incorporated2017
  • Employees581.00
  • Location
    Dizal Jiangsu Pharmaceutical Co LtdNo.199 Liangjing RoadPudong New DistrictSHANGHAI 201203ChinaCHN
  • Phone+86 2 161095757
  • Fax+86 2 158387361
  • Websitehttp://www.dizalpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Bio-Thera Solutions Ltd825.18m-377.67m9.83bn1.17k--11.61--11.92-0.9121-0.91211.992.050.35331.006.83707,092.40-16.17-23.62-26.76-30.8169.8179.76-45.77-106.720.716-27.470.4531--54.86--17.87---3.78--
Mabwell Shanghai Bioscience Co Ltd169.42m-1.07bn9.99bn1.40k--5.21--58.97-2.69-2.690.4244.800.03790.0899.74113,628.50-24.10-37.61-30.74-45.9590.5081.54-636.41-2,112.261.25-41.980.5339--361.0327.88-10.28--17.35--
Joinn Laboratories China Co Ltd2.12bn-912.86k13.26bn2.59k--1.81--6.24-0.0064-0.00642.8210.680.21510.77147.32---0.098.99-0.10611.0731.8346.76-0.418432.012.851.250.008923.814.7842.20-63.0429.668.2123.46
InnoCare Pharma Ltd898.92m-375.51m13.35bn1.09k--3.46--14.85-0.2325-0.23250.5373.860.09221.323.73825,457.90-4.02---4.78--84.50---43.57--7.65--0.1547--18.09--28.80------
RemeGen Co Ltd1.52bn-1.55bn15.44bn3.62k--7.98--10.14-2.88-2.882.834.350.27120.44465.00421,122.40-27.65-18.66-36.21-23.6978.6581.64-101.95-102.210.9558-32.190.5167--40.26141.16-51.30--59.07--
Sinocelltech Group Ltd2.45bn-24.64m19.14bn2.33k------7.83-0.0553-0.05535.49-0.28740.81460.46245.261,048,041.00-0.8674-40.17-2.70-74.6395.8395.42-1.06-108.200.5885.451.05--84.46264.1923.70--37.54--
Dizal Jiangsu Pharmaceutical Co Ltd389.64m-837.22m19.19bn581.00--44.80--49.26-2.04-2.040.94711.030.2350.40336.15670,632.10-56.00-46.02-83.89-52.9997.1757.53-238.28-2,081.541.66-193.390.674----18.29-50.50--21.35--
Shanghai Allist Pharmaceuticals Co Ltd3.20bn1.30bn25.02bn1.04k19.305.15--7.812.882.887.1210.810.68113.6011.383,068,832.0027.570.640530.380.693394.4396.4240.472.546.89--0.0003211.88155.14237.34393.54--13.53--
Data as of Sep 13 2024. Currency figures normalised to Dizal Jiangsu Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

24.10%Per cent of shares held by top holders
HolderShares% Held
Penghua Fund Management Co., Ltd.as of 30 Jun 202411.05m9.34%
China Fund Management Co., Ltd.as of 30 Jun 20242.80m2.37%
Huashang Fund Management Co., Ltd.as of 30 Jun 20242.80m2.37%
China Universal Asset Management Co., Ltd.as of 30 Jun 20242.64m2.23%
Harvest Fund Management Co., Ltd.as of 30 Jun 20241.77m1.50%
Bank of China Investment Management Co., Ltd.as of 30 Jun 20241.64m1.39%
Bosera Asset Management Co., Ltd.as of 30 Jun 20241.64m1.38%
Yinhua Fund Management Co., Ltd.as of 30 Jun 20241.43m1.21%
China Asset Management Co., Ltd.as of 30 Jun 20241.40m1.19%
Ping An Fund Management Co., Ltd.as of 30 Jun 20241.33m1.12%
More ▼
Data from 30 Jun 2024 - 29 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.